JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.08 -6.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.07

Max

3.24

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+29.97% upside

Dividendes

By Dow Jones

Prochains Résultats

17 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

159M

1.2B

Ouverture précédente

9.18

Clôture précédente

3.08

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 févr. 2026, 23:57 UTC

Résultats

Naver Has Record Year Despite Weaker Final Quarter

5 févr. 2026, 23:45 UTC

Actions en Tendance

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 févr. 2026, 22:26 UTC

Résultats

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 févr. 2026, 22:00 UTC

Résultats

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 févr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5 févr. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 févr. 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 févr. 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 févr. 2026, 23:20 UTC

Résultats
Acquisitions, Fusions, Rachats

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 févr. 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 févr. 2026, 23:09 UTC

Résultats

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 févr. 2026, 23:08 UTC

Résultats

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 févr. 2026, 23:07 UTC

Résultats

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 févr. 2026, 23:03 UTC

Market Talk
Résultats

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 févr. 2026, 23:03 UTC

Résultats
Acquisitions, Fusions, Rachats

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 févr. 2026, 23:00 UTC

Résultats

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 févr. 2026, 23:00 UTC

Résultats

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 févr. 2026, 22:59 UTC

Résultats

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 févr. 2026, 22:59 UTC

Résultats

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 févr. 2026, 22:52 UTC

Résultats

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 févr. 2026, 22:45 UTC

Résultats

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 févr. 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 févr. 2026, 22:11 UTC

Résultats

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 févr. 2026, 22:03 UTC

Résultats
Acquisitions, Fusions, Rachats

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 févr. 2026, 22:01 UTC

Résultats

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 févr. 2026, 21:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 févr. 2026, 21:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

5 févr. 2026, 21:49 UTC

Résultats

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 févr. 2026, 21:45 UTC

Résultats

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

29.97% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  29.97%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat